Dr. Girindra Raval, associate professor in the Department of Medicine, Hematology and Oncology at the Medical College of Georgia and Georgia Cancer Center, shared insights with CURE about treatment options for patients with EGFR-mutated lung cancer, emphasizing recent advances in targeted therapies.
“EGFR-mutated lung cancer is a unique entity,” Raval explained. “We often see it in non-smokers and female patients. Data show that targeted EGFR therapies outperform standard chemotherapy for patients who have undergone surgery or local chemoradiation.”
For early-stage patients, Raval noted, targeted therapy after local treatment leads to significantly better outcomes than traditional chemotherapy. However, he cautioned that immunotherapy, a widely discussed treatment for lung cancer, has shown limited efficacy in this subgroup.
EGFR mutations occur in about 20% of non-small cell lung adenocarcinoma cases, making it the second most common targetable mutation after KRAS. In metastatic cases, recent studies indicate that newer therapies can improve overall survival.
“Each treatment advance comes with potential side effects,” Raval said. “It’s crucial for patients to discuss these with their thoracic oncologist or healthcare provider. Newer treatment combinations, such as oral TKIs paired with chemotherapy, can be more potent but also carry unique risks.”
He highlighted the MARIPOSA study, which tested Rybrevant (amivantamab) with Lazcluze (lazertinib). While more effective than earlier drugs like Tagrisso (osimertinib), this combination may cause side effects such as leg swelling, blood clots, skin reactions, low blood counts, and other toxicities. Patients may require preventive measures, including blood thinners for the first few months.
Emerging therapies like Datroway (datopotamab deruxtecan) have also shown promise in extending progression-free survival. However, these drugs can cause dry eyes, mouth sores, interstitial lung disease, and other side effects. Early detection and communication with healthcare providers are essential to manage these risks.
“Awareness and vigilance are key,” Raval emphasized. “By understanding potential side effects and maintaining open communication with their medical team, patients can safely benefit from the latest advancements in EGFR-mutated lung cancer treatment, which continue to improve survival outcomes.”
Related topic：
